Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

Westernization Associated With Potentially Harmful Sun Habits Among Asian Americans
Asian Americans who have adopted more aspects of Western culture may be more likely to engage in behaviors that increase sun exposure, thereby endangering their skin health, according to a report in the May issue of Archives of Dermatology, one of the JAMA/Archives journals.

Sedatives May Increase Suicide Risk In Older Patients
Sleeping tablets have been associated with a four-fold increase in suicide risk in the elderly. Researchers writing in the open access journal BMC Geriatrics have shown that, even after adjusting for the presence of psychiatric conditions, sedatives and hypnotics were both associated with an increased risk of suicide.
News of the day
Nurses And Midwives Looking For Real Reforms, Australia
The Federal Secretary of the Australian Nursing Federation, Ged Kearney and the Assistant Federal Secretary, Lee Thomas will be available for comment on the Prime Minister"s address on the challenges of Health Reform and the release of the NHHRC report.
Public Health

Meda: Positive Study Supporting A Potential Once-Daily Nasal Antihistamine

In October 2008, the US Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for the newly formulated higher strength azelastine nasal spray as complete for substantive review after initial evaluation. This NDA contained data on six phase III studies and a long-term safety study, involving more than 1,600 patients in total. In these clinical studies, the product demonstrated improvement in nasal symptom relief scores in patients with seasonal and perennial allergic rhinitis, and was well tolerated. Parallel to FDA"s review process, Meda initiated a seventh phase III study. This study has now been completed and the results support a potential claim for a once-daily administration. Meda has decided to add this study to the submitted NDA. In response, FDA has requested three additional months to review this new information. Therefore, Meda anticipates a formal response on this NDA during September 2009. MEDA AB


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009